

2018

## Experiences of Australian men diagnosed with advanced prostate cancer: A qualitative study

Suzanne K. Chambers  
*Edith Cowan University*

Melissa K. Hyde

Kirstyn Laurie

Melissa Legg

Mark Frydenberg

*See next page for additional authors*

Follow this and additional works at: <https://ro.ecu.edu.au/ecuworkspost2013>



Part of the [Medicine and Health Sciences Commons](#)

---

10.1136/bmjopen-2017-019917

Chambers, S. K., Hyde, M. K., Laurie, K., Legg, M., Frydenberg, M., Davis, I. D., ... & Dunn, J. (2018). Experiences of Australian men diagnosed with advanced prostate cancer: a qualitative study. *BMJ open*, 8(2), e019917. Available [here](#).

This Journal Article is posted at Research Online.  
<https://ro.ecu.edu.au/ecuworkspost2013/4726>

---

**Authors**

Suzanne K. Chambers, Melissa K. Hyde, Kirstyn Laurie, Melissa Legg, Mark Frydenberg, Ian D. Davis, Anthony P. Lowe, and Jeff Dunn

# BMJ Open Experiences of Australian men diagnosed with advanced prostate cancer: a qualitative study

Suzanne K Chambers,<sup>1,2,3,4,5,6</sup> Melissa K Hyde,<sup>1,2</sup> Kirstyn Laurie,<sup>1,2</sup> Melissa Legg,<sup>1,2</sup> Mark Frydenberg,<sup>3,7,8</sup> Ian D Davis,<sup>3,9</sup> Anthony Lowe,<sup>1,3,4</sup> Jeff Dunn<sup>1,2,3,5</sup>

**To cite:** Chambers SK, Hyde MK, Laurie K, *et al.* Experiences of Australian men diagnosed with advanced prostate cancer: a qualitative study. *BMJ Open* 2018;**8**:e019917. doi:10.1136/bmjopen-2017-019917

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-019917>).

Received 7 October 2017  
Revised 19 January 2018  
Accepted 26 January 2018



<sup>1</sup>Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia

<sup>2</sup>Cancer Research Centre, Cancer Council Queensland, Brisbane, Queensland, Australia

<sup>3</sup>Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Sydney, New South Wales, Australia

<sup>4</sup>Prostate Cancer Foundation of Australia, Sydney, New South Wales, Australia

<sup>5</sup>Institute for Resilient Regions, University of Southern Queensland, Toowoomba, Queensland, Australia

<sup>6</sup>Health & Wellness Institute, Edith Cowan University, Perth, Western Australia, Australia

<sup>7</sup>Department of Urology, Monash Health, Melbourne, Victoria, Australia

<sup>8</sup>Department of Surgery, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia

<sup>9</sup>Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia

## Correspondence to

Professor Suzanne K Chambers; [suzanne.chambers@griffith.edu.au](mailto:suzanne.chambers@griffith.edu.au)

## ABSTRACT

**Objective** To explore men's lived experience of advanced prostate cancer (PCa) and preferences for support.

**Design** Cross-sectional qualitative study applying open-ended surveys and interviews conducted between June and November 2016. Interviews audio-recorded and transcribed verbatim and analysed from an interpretive phenomenological perspective.

**Setting** Australia, nation-wide.

**Participants** 39 men diagnosed with advanced PCa (metastatic or castration-resistant biochemical progression) were surveyed with 28 men subsequently completing a semistructured in depth telephone interview.

**Results** Thematic analysis of interviews identified two organising themes: lived experience and supportive care. Lived experience included six superordinate themes: regret about late diagnosis and treatment decisions, being discounted in the health system, fear/uncertainty about the future, acceptance of their situation, masculinity and treatment effects. Supportive care included five superordinate themes: communication, care coordination, accessible care, shared experience/peer support and involvement of their partner/family.

**Conclusions** Life course and the health and social context of PCa influence men's experiences of advanced disease. Multimodal interventions integrating peer support and specialist nurses are needed that more closely articulate with men's expressed needs.

## INTRODUCTION

Prostate cancer (PCa) is the second most common cancer in men with the highest incidence in Australia/New Zealand and North America.<sup>1</sup> Most men present with localised disease or disease with regional lymph nodes spread with the relative 5-year survival rate for these men exceeding 95%.<sup>2-3</sup> However, one in five will progress to metastatic disease.<sup>4</sup> Approximately 5% of men are diagnosed with metastatic disease and the relative 5-year survival rate for these men is only 30%.<sup>3,5</sup> The mainstay treatment for advanced PCa is androgen deprivation therapy (ADT) that typically is followed by progression to metastatic castration-resistant PCa.<sup>6</sup> Once this occurs, median

## Strengths and limitations of this study

- Extends previous research in men with advanced prostate cancer to describing how masculinities, life course and the broader social and public health context influence support needs.
- Robust and transparent study method and the application of a phenomenological approach.
- Valid and reliable and transferable within the Australian setting.
- Cross-sectional design is a study limitation.

survival is less than 2 years,<sup>7</sup> although recent therapeutic advancements such as abiraterone acetate and enzalutamide have shown potential for further slowing disease progression<sup>8</sup> with median survival up to 3 years.<sup>6</sup> The STAMPEDE<sup>9</sup> and LATITUDE<sup>10</sup> trials demonstrated a survival advantage for the combined use of abiraterone with commencement of ADT; however, this was offset by earlier and more prolonged androgen suppression and a higher risk of grade 3–5 adverse events.

Hence, while new treatments for advanced PCa prolong life, this means men are living longer with the effects of treatment and disease progression including deteriorating bone health, pain, hot flushes, loss of libido, erectile dysfunction, increased fat mass, sarcopenia, fatigue and cognitive decline.<sup>6,11,12</sup> Men with advanced PCa have poorer quality of life, higher levels of psychological distress, increased suicide risk and more unmet supportive care needs compared with men with localised disease.<sup>13–16</sup> Approximately one in four experience regret about treatment decisions and this is associated with poorer quality of life and increased distress.<sup>17</sup> In sum, the burden associated with advanced PCa is substantial and further evolving as new treatments emerge.

To date there is scant psychosocial or supportive care intervention research directly targeting men with advanced PCa and the one randomised trial of scale completed by our team failed to prove effectiveness.<sup>15 18</sup> Researchers in Canada and Scotland have previously highlighted the persisting support services gap for men with advanced PCa and suggested more qualitative research elucidating men's experiences is needed if we are to develop effective supportive care interventions.<sup>19 20</sup> Carter *et al* in 2011 explored the supportive care needs of men with advanced PCa and concluded that functional issues, information needs and emotional distress were the three domains of need that needed to be addressed.<sup>19</sup> More recently, Paterson *et al* (2017) interviewed eight men with advanced PCa describing a broader range of challenges extending to interpersonal and intimacy needs.<sup>20</sup> Both studies emphasised the gap in informational support for these men; however, neither deeply explored issues related to masculinities nor the broader social and public health context in which this illness experience is nested.<sup>21-23</sup> We sought to extend this previous work more specifically connecting our enquiry between men's challenges in facing advanced PCa and their preferences for support within their social context. Accordingly, we applied an interpretative phenomenological approach to describe the lived experience of men with advanced PCa (proven metastatic or castration-resistant biochemical regression) and their supportive care preferences.

## METHOD

### Study design

This study applied a cross-sectional qualitative design. In a first step, participants reflected on their experience with advanced PCa via a mail administered open-ended survey. These responses provided a context to inform development of a protocol to guide subsequent semi-structured in-depth telephone interviews. Consistent with the study aim to describe men's lived experiences in the context of advanced PCa, we adopted an interpretative phenomenological perspective.<sup>24 25</sup>

### Participants and recruitment

Participants were recruited from an existing patient cohort.<sup>15</sup> In brief, this was a cohort drawn from treatment centres across Australia with participants from five Australian states. In June 2016, we contacted men who had not withdrawn from the cohort and were not to our knowledge deceased and had consented to future contact (n=141). In all, 39 men returned the survey (28% response) and of these 28 were available for telephone interview between September 2016 and November 2016 (72% response). Similar to the cohort from which participants were drawn, the mean age of participants was 72.7 years (SD=8.5; range 58.2-94.6) with the majority born in Australia (75%), married (86%) and retired (79%); men resided across four

**Table 1** Sociodemographic characteristics and treatment information for participants completing an open-ended survey and telephone interview

Participant ID	Age (years)	Time since diagnosis (years)	Received hormone treatment (Y/N/NR)
P3	70	8.0	Y
P5	67	NR	NR
P6	90	4.2	Y
P7	69	4.3	Y
P8	69	7.0	Y
P9	69	3.9	Y
P10	86	3.2	Y
P12	72	14.4	Y
P14	67	4.0	Y
P15	71	11.5	Y
P17	95	10.3	Y
P18	75	16.0	Y
P19	78	5.4	Y
P20	69	5.8	Y
P21	70	15.1	Y
P23	79	12.0	Y
P24	72	22.8	Y
P25	61	2.7	Y
P26	76	7.8	Y
P27	64	8.1	N
P30	58	6.0	Y
P31	59	4.8	N
P32	70	4.2	Y
P33	74	6.8	Y
P34	70	6.0	N
P35	78	4.4	Y
P38	76	NR	NR
P39	83	2.1	Y

N, no; NR, not reported; Y, yes.

Australian states. With regard to educational level, 7 men had a college degree, 15 had a trade or technical certificate/diploma, 2 had completed senior high school and 4 had completed junior high school. Mean time since diagnosis was 7.7 years (SD=5.0; range 2.1-22.8). Most men were treated with ADT (88%), 73% radiation therapy and 62% prostatectomy. Men who did not participate were either too unwell (n=4), had a hearing impairment (n=1) or did not consent (n=6). **Table 1** reports sociodemographic characteristics and treatment information for each interview participant.

### Data collection

Men responded to four questions in the survey about their PCa-related concerns: assistance or support accessed for

**Table 2** Interview questions

Focus area	Question
Health system	Thinking about your medical treatment, what changes do you feel would make medical services better meet the needs of men with advanced prostate cancer?
Supportive care needs	Thinking about the treatment side effects that a man with advanced prostate cancer might experience, what sort of support would help most? Thinking about the future and the worries that face a man with prostate cancer that has advanced or recurred, what sort of support would help most?
Barriers	In developing services to help men cope or manage better with advanced prostate cancer, can you describe support approaches or ways of helping that would not be acceptable to men? For example, supportive approaches that would turn men off or away?
Preferred approaches	In developing services to help men cope or manage better with advanced prostate cancer, can you describe support approaches or ways of helping that would be more attractive to men?
Other	Thinking about what we have spoken about today, is there anything else we haven't covered that you think is important to supporting men with advanced prostate cancer?

these concerns and from whom, other support needed and preferences for support for men. Thematic analysis<sup>26</sup> of responses (MKH, KL, SKC) indicated four areas that were challenging for men and in which they lacked support: information, medical care, side-effects and the future. Three experienced female interviewers in a research fellow or research assistant position with post-graduate training in the behavioural sciences (ML, KL, EE) conducted telephone interviews to further explore the key areas identified. Interviews were on average 62.1 min in length (SD=19.2; range=29.2–111.9 min). Member checking occurred at the beginning of each interview during which the interviewer asked participants to comment on the accuracy of researcher interpretation of survey results and gave participants the opportunity to add anything they thought had been missed. Interview questions (table 2) explored in greater depth the concerns previously identified in men's survey responses: health system concerns, supportive care needs, barriers to support and preferred approaches. Participants were invited to discuss other aspects of their experience that they considered were important. Interviews were audio-recorded and transcribed verbatim.

### Data analysis

Interview transcripts were analysed using thematic analysis.<sup>26 27</sup> Themes were derived inductively from the data by reading and re-reading the interview narratives and from this developing an understanding of men's lived experience through their words. Coders had social and behavioural science (SKC, MKH, JD, KL) and nursing (SKC) backgrounds with a wide range of experience from 2 to 20 years working in psycho-oncology and PCa research and included male and female researchers. Transcripts were coded iteratively with constant comparison between the codes generated and the data to ensure that consistent and diverging responses were incorporated. Two research team members independently coded one-third of the transcripts and generated a preliminary coding scheme (MKH, KL). This coding scheme was further refined with

a third (SKC) and fourth (JD) research team member. Once all interview transcripts were included, the coding scheme was further reviewed and agreed on by all coders. Exemplar responses were identified across transcripts to illustrate and confirm labelling of themes. Reporting of data is consistent with consolidated criteria for reporting qualitative studies (COREQ) guidelines.<sup>28</sup>

### RESULTS


Thematic analysis identified two organising themes: lived experience and supportive care. The first organising theme reflected men's lived experience with advanced PCa and within this six superordinate themes. The second organising theme captured elements of supportive care that men found challenging and their preferences for how care should be delivered with five superordinate themes. Figure 1 depicts the coding structure. Tables 3 and 4 present illustrative quotes for each superordinate theme.

#### Lived experience

Men's lived experience with advanced PCa included six superordinate themes: regret about late diagnosis and treatment decisions, being discounted in the health system, fear/uncertainty about the future, acceptance of their situation, masculinity and treatment effects (table 3).

#### Regret about late diagnosis and treatment decisions

Most men described feeling regret about late diagnosis or treatment and this was commonly attributed to delays by clinicians. Many men perceived these delays were caused by general practitioners and/or specialists who would not perform digital rectal examinations or prostate-specific antigen (PSA) testing, did not detect PCa until it was well advanced despite regular testing and did not refer patients for further treatment or testing in a timely manner despite men's requests for them to do so. From this, some men were left with a distrust of the medical



**Figure 1** Coding structure derived from thematic analysis.

profession. Many men also discussed regretting their treatment choices and not having had a second opinion so that they felt more adequately informed and clearly understood the outcomes of treatment, including side effects and how these could be managed.

#### Being discounted in the health system

In their interactions with clinicians, most men described their concerns, needs and autonomy as discounted or ignored. Many men felt devalued and believed they were somehow less important in the broader health system. In their experience, PCa was the ‘poor cousin’ of breast cancer in terms of funding, research focus and controversy over the value of PSA testing and less effort by the government and non-profits to promote awareness of PCa. Some men also considered that they and their cancer were less important due to their older age and community attitudes where PCa is considered a cancer that may not lead to death.

#### Fear/uncertainty about the future

An uncertain future was discussed in terms of most men needing to make ‘the unknowable’ a known entity by

understanding how much time they may have left to live, what lies ahead for disease progression and quality of life, potential treatment options and next steps for support when all treatment options had been exhausted. This information was critical to their ability to feel more in control and to prepare for the future both psychologically and practically while they were well enough to do so. By contrast, some men discussed not wanting to know what the future held in order to focus on their day-to-day life.

#### Acceptance

Many men used their age as a frame to accept physical changes and the threat to their mortality. Other approaches adopted by many men to reach acceptance were focusing on ‘getting on with it’, and viewing ongoing physical effects of the disease or its treatment as part of life, an inevitable outcome of treatment or disease progression and as a favourable alternative to death. Regarding sexuality, some men found changes in their physical capacity to have sex an ongoing cause of distress. Other men shifted their focus to other aspects of their relationships (eg, expressing intimacy in ways

**Table 3** Lived experience organising theme and superordinate themes

**Exemplar quotes**

**Superordinate theme**

Regret about late diagnosis and treatment decisions

"I saw a GP and first of all, I think it was 1.9 was my PSA reading, and when it got to 14 I said to him—everything I read tells me that I should be seeing a specialist. And he said, 'Oh you worrywart, don't worry about it,' and then next time I said it, he said, 'All right I'll send you to see [...] he's a urologist.' I went to see his specialist mate, and he said, 'Bloody hell, where've you been, you should've been here 3 years ago.' Because it'd been like that for 3 or 4 years. The prostate was full of cancer, and it escaped outside the prostate and went into my lymph nodes, because of all that time wasted." (P31)  
 "My only regret was that I didn't get enough information at the beginning, or hey, maybe I did, but I was never comfortable with the fact that I had really learnt everything that there was to learn about it before I actually made decisions, and I may or may not have made the wrong one." (P32)

Being discounted in the health system

"The men seemed to think that prostate cancer was a B grade compared to other cancers. Because it was older men, and they'd had their run probably. No-one's going to worry too much about it... Usually men who have got prostate cancer are old, older men and certainly you wouldn't all the funding going to the old men and not the young women, or middle-aged women. It wouldn't be fair would it. So we thought that the prostate cancer people were sort of the poor relations in both attitude, funding, in a lot of ways. But you can't change it." (P26)  
 "They treat you more as a joke, yeah, and the last time I spoke to him about it— I tried to find out am I going to have a lot of pain, is my bones going to break or whatever? He said: You'll probably die of pneumonia." (P6)  
 "I just got the impression that the patient was just a number, the name didn't matter, in fact, we won't even involve the patient in the discussion, they're there but we've just got a number for him on the records and when they come around to your bed the team, which could be a half a dozen or 10 or even more depending on how many people they've got on the day, they just start talking about the condition you've got, absolutely nothing, no mention of you yourself being the patient, they don't even recognise you." (P20)

Fear/uncertainty about the future

"I'd just like to know where I'm headed. I guess he can't tell me what's going to happen with the disease, but I'd imagine there must be a pattern, a reasonable pattern of what happens. I mean, with some illnesses you know this is going to progress from this to that, to that, but an article I saw recently in a support group pamphlet was, if you took Drug X tablets, when they stopped working, you took Drug Y tablets. When they stopped working, the next thing on the —on the ladder was death, d-e-a-t-h. Well, I've been taking Drug X for quite a while. I've been taking Drug Y for quite a while. Each had a definite effect on my PSA, each lost that effect. So really, the next thing that faces me is death. Now, so, it was 4 months ago that my oncologist gave me, he said, 'You'll see your birthday.' Well, that's only 3 months away, it's only 2 months away actually. What's going to happen between now and then?" (P6)

Acceptance

"I think acceptance. That would be the word that comes to mind. Not resignation, big difference in my mind between resignation and acceptance, but okay, I accept it, to live a bit longer, or feel a bit better (erectile dysfunction). This is what happens, I've just got to come to terms with it the best way I can. I didn't handle it too well. I think even at that age, you think you're indestructible. Gees, it did happen. But, it's not the end of the world and that's the attitudinal part, I think, more so than—attitude in retrospect, acceptance and spirituality part of it... I can possibly liken it, sort of, something akin to grief counselling is what I needed. You know, there's anger, there's frustration, everything. The whole gambit. It's all there. It's like, okay, it's passed away now, you know, let it rest... I just assumed, pop a couple of Viagra, you'll be right. But, no. So, yeah, it's—yeah and that's a problem after being very active for such a long time with a beautiful wife, it's really hard, really hard to take." (P30)

Masculinity

"Partly, I think, the reluctance of men to talk about their health, or to talk about personal issues that the idea of maleness, being able to be stoic and cope, type of thing. And just in the idea of maleness, that, sort of, men don't cry, men are stoic, or you get on and cope with things, a lot of men have not been exposed to talking about personal matters and so find it difficult to do that." (P9)

Continued

Table 3 Continued

Superordinate theme	Exemplar quotes
Treatment effects	<p>“I’m impotent, and that—put it this way, that’s—honestly, that’s something that I have an extremely hard time coming to terms with. My wife and I had a fantastic sex life but that’s gone and there’s now—yeah, it’s probably as much my fault as hers but there’s just nothing left of our marriage; we live together but that’s about it.” (P38)</p> <p>“I can’t even walk down the beach, put out—not having to urinate a couple of times, I take my dog for a pretty long walk each day and I’m looking over my shoulder and I’m always thinking one day I’m going to get busted and someone’s going to call me a dirty old man and are they going to even be prepared to listen to the fact that I’ve had prostate cancer and it’s not my fault?” (P14)</p> <p>“Eating is a problem, I have a problem eating. I don’t really want to eat but I more or less force myself to eat, because I have no energy, but I’ve lost, I think, it’s 40 kilos all together, but that’s over a period. When I look in the mirror I see this gaunt face looking at—I thought I was fairly good looking for an old bloke but now I really look bloody painful, I take notice, like, god I’m gaunt. And I really am thin.” (P19)</p> <p>“The general fatigue, loss of energy, loss of muscle tone, the hormonal issues were probably the biggest ones. I’ve got osteoporosis because—it’s only at the early stage, but my bone density is checked regularly, but it’s dropping slowly even though I do exercise, walk a lot and keep my weight down and exercises up. I do that sort of thing all the time. But I’m probably holding it in check. But that one’s always a bit of a concern. I’ve got to be careful I don’t fall off the roof, I don’t do something, don’t break anything nowadays. In fact I—when I finished radiation therapy I felt all pretty smart and I went running on the rocks at the beach one day, and jumped from one rock to another, and snapped my ankle so badly it had to be screwed up with screws and braces.” (P5)</p> <p>“I now have gynaecomastia which I’ve discussed with my GP and my specialist. I was looking at having my breasts removed, unfortunately which I would’ve had to pay for, but I was told that if I did, they would come back so it would be a waste of time and effort and money doing it.” (P38)</p> <p>“I know the cancer’s spreading. I woke up this morning about 4 o’clock with pains in my pelvic, where it is, the pelvic bone where I suspect the cancer’s moving to. They said it would be at the Cancer Clinic, so that gave me a bit of pain. But I find if I take Panadol, one of these Panadols—I take two at night and two in the morning and two midday, I keep the pain at a level that’s quite acceptable. But I didn’t take it last night and then I woke up at 4 o’clock and thought, oh, what’s going on here.” (P23)</p> <p>“I mean one of the biggest impacts is financial loss and that is not discussed full stop. That’s when you’re diagnosed with a terminal illness and there is no cure. They can slow the disease down, which they’ve successfully done in my case. But because of the side effect of loss of testosterone, so you’ve got less energy, muscle wastage and all of that. And the end resulted in me—I had to give up work. Now, that financial loss has been a big impact on my retirement and everything else.” (P3)</p>



**Table 4** Supportive care organising theme and superordinate themes

**Superordinate theme**

**Exemplar quotes**

Communication

“For me at my stage, or more advanced, or—I don’t know at what stage I’m at. Whether I’m advanced or reasonable, or what. I don’t have any—I don’t have any real—I don’t know what the symptoms are—if you do get advanced or more advanced, I don’t know what the symptoms are really. I have no information in that regard. I don’t know.” (P17)  
 “He’s not exactly verbose, he doesn’t say a great deal. And I got put on Drug Z and was more or less left to my own devices with my GP who I don’t think he’d ever heard of it and it wasn’t really until about 3 or 4 months ago that we managed to sort out how the injections should be given.” (P10)  
 “Openness, I think, for me for the treatment options. Probably the side effects were less discussed or less publicised. There was some, particularly in the radiation process, you could get burning, you could get itching, this, or that, but then later on you find out there was some others that they didn’t mention...On that score, I think there’s some minor explanation, you will get tired, you will get hot flushes, but no advice—what can you do about a hot flush; go and have a cold shower. There’s been nothing on that, and in terms of maybe a medication, is there something will help as it does for ladies, I’ve got no idea.” (P35)

Care Coordination

“You just get the impression going through the process that the different stages of the process all have their own people, their own separate team altogether. I guess, I could sum it up in a word and that’s coordination with all the different treatments and tests and results and everything to do with the treatment, all those things are there obviously, patients are being treated for a long, long time, but having been through the process I just find that even though you end up getting through it it’s a bit of a minefield for the patient because they haven’t got a clue really what’s involved, what’s coming next, what you’ve got to do.” (P20)  
 “It’s got to be the doctors. The doctors, I think, it has to start at the GP level and go right through. This is, as I say, this is your life and they’re doing the journey with you. That’s a good way of putting it, they’re doing the journey with you.” (P15)  
 “I’d say ideally at time of diagnosis, after you talk to the doctor the next step would be the prostate cancer nurse. Yeah. Into the treatment part of it, yes, as part of the treatment process. But, in some ways, I think, that if you’ve got, say, sort of a trusted person, so if it’s a prostate cancer nurse providing good information and directing traffic, type of thing, and putting people in touch with resources, I think, that’s probably going to help to overcome the difficulties.” (P9)  
 “I think this support idea needs to be built in at diagnosis level into the, well, the doctors would present this as, “This is a natural part of the treatment, we’re not saying go there if we think you need it, you have been diagnosed with cancer, you need it, we would strongly recommend you take your—take the benefit of going to a group for, I don’t know how many meetings, but a few. And I also think that—how you do it I don’t know, but that it gets presented—it is presented to men as, “This is what you do, there is no loss of dignity in going and talking over your problems with people who are in the state—in the same position as you are.”” (P39)

Accessible care

“Well I’m up in the country and when I got diagnosed there was really no services in my town and it was a, you know an hour and a half trip to the closest place where could get anything done...Well they certainly—they didn’t even have chemotherapy services here. And they didn’t have helpers such as prostate nurses etcetera, people that were specifically trained in this sort of cancer. My oncologist, my urologists are all down in Melbourne. I mean they’re 2 hours away in a motor car.” (P34)  
 “It’s about \$4000 a year. I think it’s about 4 to 12, about \$4000 a month I think. Which the majority of people can’t afford anyway. So he’s got a number of other drugs, too. But that’s the one he’d like to use next for me. So we’ve got to deal with that when we get there.” (P5)  
 “I definitely would (go to another support group). The problem is I can’t drive anywhere at the moment because of some of the drugs I’m on; so it makes it very difficult for me to get anywhere. And now the closest group other than this one, even that one I had to go by car, but the next area’s group is probably about twice the distance away and nowhere near public transport.” (P27)

Continued

Table 4 Continued

Superordinate theme	Exemplar quotes
Shared experience/peer support	<p>“And I think that’s—the big help that people need, and they are finding it here because they come to support group, it’s looking for some comfort, I think, or some advice, or to talk to someone who’s been there and done that. I think that a lot of trouble with the GPs and the surgeons, they—a lot of them don’t have that first-hand experience, even though they work with it every day of their lives they don’t—they haven’t had the actual experience of living with the disease first-hand anyway.” (P5)</p> <p>“I think if you had someone or a little group of people who could meet and talk and have—maybe even in a coffee shop, have a cup of coffee, even the pub, have a beer or coffee or something and discuss your problems because that’s where you’ll find out that most of the people have problems the same as you. You get some men together, you can have someone facilitate it at first, then you just leave them and come back later on.” (P19)</p> <p>“Yeah, well face-to-face is the best way, but yeah, online, why not? Particularly with people in the country, assuming they know how to go online and handle IT and all that sort of thing. Yeah, somebody or some group of people that they can contact who do have the experience and have the understanding.” (P21)</p> <p>“From a personal standpoint of view, the normal sort of prostate cancer support group hasn’t been of any real benefit to myself or my wife. And the reason advanced prostate cancer for now, based in south east Queensland, which covers all of Australia and we have a monthly telephone conference and that is, yeah that’s quite beneficial. Because everybody in it has got advanced prostate cancer. It’s just that yeah, I’ve got advanced metastatic prostate cancer and that’s what this group is particular for, for men with advanced. Because we joke and say we among ourselves, ‘Dead Men Walking Club.’ Warped sense of humour.” (P3)</p> <p>“And, I know, I found going to the support group, I walked into the room, I sat by myself and I didn’t sort of mix with the other men, but that unfortunately is me. I’m not a mixer, I’m not a conversationalist, although I seem to be talking pretty well to you. So I found them, it felt a bit uncomfortable. For those who have been there a long time, they were starting to hear the same thing over and over again. So I guess that might have been why I terminated going, one of the reasons. Very well run group, I just lost, I felt I was getting no benefit out of it and I wasn’t really comfortable there. That’s me, my particular makeup you can understand.” (P6)</p>
Involvement of partner/family	<p>“She (wife) senses my feelings, my moods, and she can tell if I’m feeling a bit negative by my comments or my talk, or mostly my body language. And she doesn’t beat around the bush, she just tells me to snap out of it, or, ‘Pull yourself together,’ or ‘get yourself sorted’. ‘Why don’t you do this, or why don’t you do that?’ She doesn’t muck around, she really socks it to me, which is really good, it’s what I need. And I know that a lot of men say the same thing, they are always grateful for their partners in many, many cases, and we really live a lot longer with good wives, I can assure you. My wife is definitely the the pinnacle. She’s the main support there.” (P5)</p> <p>“So, I help with transport and I have someone come and help me clean once a fortnight and that, but I probably need help with shopping, but I have friends who will go and do the shopping or take me shopping. So, I’m fairly well off in that regard. So, yeah, it’s good to have someone who will help you, you don’t want them mothering you, but take you and if I needed shopping we would go shopping after we’d been to the gym, heavy shopping, I need it, and bring it home.” (P19)</p>

that do not require an erection) as a way to accept their situation.

### Masculinities

Male values and masculinities were discussed as central to most men's experience of PCa, support and coping. Many men believed that as a group they do not look after themselves, go to the doctor, ask for help or talk about their problems by comparison to women and have a different view on their health, are less prepared to discuss their health and gave health less attention. This reluctance to seek help or support or talk about their problems was ascribed to male values around being strong, capable, independent/autonomous or stoic. Many men used avoidance as a coping approach by avoiding thinking or talking about their situation and covering up or ignoring side-effects or a need for support. Some men expressed concerns that there would be negative consequences socially or in their employment if others knew about their cancer. Privacy and being embarrassed talking about personal issues were also raised by many men. Viewing sexuality and sexual function as important to their identity as a man meant that some men were deeply troubled by changes in sexuality and believed that their relationship with their partner now would be negatively impacted or that it would no longer be possible for them to start new relationships with women.

In their perceived role as 'the provider' and 'the protector', some men expected to give help rather than receive it. Some men tried to protect their wives or their family by not talking about their problems and thus avoid worrying them. Many also adopted approaches to promote adjustment including being optimistic and 'getting on with it', taking responsibility for their health and well-being (eg, remaining physically active) as well as an action-oriented approaches in which they identified and solved problems directly or sought help or support. In using these approaches, men saw themselves as uninhibited by masculine norms, which typically constrain help seeking. Many men devalued 'talk' as a way to obtain support and viewed psychologists as not able to provide the solutions they needed, also describing unfavourable attitudes towards support groups as an opportunity for self-pity or drama.

### Treatment effects

All men discussed the effects of advanced PCa and its treatment that affected their quality of life, relationships, capacity to do daily tasks and for many men were highly distressing. Prominent among these were physical effects and financial concerns. Physical effects included the inability to obtain an erection, lack of libido, urinary incontinence, changes in appearance and bodily structure including gynecomastia, weight gain, sarcopenia, decreased bone density, fatigue, dizziness, loss of balance, breathlessness, hot flushes, cognitive changes and pain. Some men discussed no longer being well enough to work and that this negatively affected their income and retirement plans.

### Supportive care

The organising theme supportive care included five superordinate themes: communication, care coordination, accessible care, shared experience/peer support and involvement of their partner/family (table 4).

#### Communication

Men had mixed experiences in their interactions and communication with health professionals. Four pivotal points in the care trajectory in which effective communication appeared most critical were: diagnosis, deciding on treatment options, treatment effects and symptom management and follow-up care. Many men described being unclear about the specifics of their diagnosis (eg, staging, PSA) whereas, by contrast, some men appreciated the direct and honest approach adopted by their clinicians when communicating about the severity of their disease. When discussing treatment options, men desired more guidance and support in making a treatment decision and for options to be more clearly communicated so that they could better understand long-term treatment effects. Some men were dismayed that their general practitioners (GP) or other health professionals did not seem to have specialised knowledge about PCa. Preferred decision support included clear, unbiased communication about the pros and cons of each treatment option and referral to other sources of information that men could consider in their own time.

Some men described confusion and frustration when they were given a treatment that they needed to self-administer (eg, injections) but were not effectively instructed in how to do this. Men commonly discussed health professionals' communication about treatment side-effects as insufficient (eg, told about effects but not how to deal with them) and selective (eg, told about immediate but not long-term effects) and as a consequence felt unprepared and isolated in their experience. Some men described not being listened to when they raised their concerns or being unable to get clear answers to questions. Some men expressed that it was up to them to find solutions to manage their side-effects because clinicians did not adequately address these.

#### Care coordination

For some men, regular ongoing communication with their clinicians was a source of support; however, other men felt out of touch and isolated due to the length of time between each consultation. GPs were important to some men in helping them feel connected with their care team. Most men discussed the need for better coordinated care and information and this was focused on three aspects: communication between health professionals, having a 'middle man' and integrating psychosocial support as part of routine care.

A lack of communication between specialist clinicians regarding treatment and referral was discussed by many men as problematic. Men had mixed views as to who should be the central point of call for information and

referral. Some men believed this should be their GP; others suggested their urologist or oncologist. Patient advocates or navigators were also discussed by some men as an option to help streamline and clarify the diagnostic and treatment process. Some men discussed PCa nurses as being central to their care. Nurses provided informational, emotional and practical support that clarified men's understanding of their situation, served as an intermediary between the patient or couple and other clinicians and were seen as more likely to refer them to other beneficial services than other healthcare professionals. These men discussed that the best time to be connected with a PCa nurse was at diagnosis with continued access throughout treatment.

Some men identified the need to integrate psychosocial support as part of routine care without relying on men themselves to raise emotional issues with clinicians. Alongside this, some men also discussed the need for routine referral to support groups or information about the existence of local groups and exercise programmes as helpful for weight gain and muscle wastage and managing feelings of loss of masculinity.

#### Accessible care

Many men discussed three main barriers to accessible care: geographic location, ill health and financial cost of treatment. Some men experienced difficulty accessing services because they resided in a regional or rural location where services were either not available or required them to travel long distances with resultant cost and inconvenience. Some men had difficulty or were prevented from accessing central or nearby services due to ill health or fatigue; and some men discussed the high financial cost of treatments or drugs to manage side-effects such as erectile dysfunction and uncertainty about how to cover these costs. To overcome accessibility issues, these men suggested use of online or telephone services for those in rural or regional areas or who could not access care due to ill health, lobbying the government to subsidise financial costs of treatment and increasing the availability of home-based medical care or practical assistance services.

#### Shared experience/peer support

The opportunity to talk to other men in the same situation was discussed by most men as a source of support that they had, or wished they had, an awareness of and access to. Three aspects of shared experience/peer support: benefits, delivery preferences and barriers were described. Shared experience was highly valued by most men because it allowed them to talk to someone who had been through the same experience, obtain information or advice when weighing up treatment decisions or managing side effects, make positive upward (eg, other men doing well and inspiring hope for recovery) or downward (eg, other men are doing worse so I am ok) comparisons,<sup>29</sup> gave men a safe and confidential forum to express their concerns and helped men to feel less alone. However, some men did not associate peer support or

being connected to support groups with the concept of sharing mutual experiences. Rather discussed it in relation to the naturally occurring companionship with other men from social or sporting clubs or Men's Sheds.

Most men proposed different delivery methods for peer support (eg, face-to-face, telephone or online) to take into account individual differences and need for privacy or anonymity. Both structured (eg, with a facilitator and an agenda) and unstructured (eg, a chat over coffee) methods were acceptable. Some men preferred shared experiences specifically for men with advanced disease on the basis that men with localised disease have different treatments and cancer-related physical effects.

Finally, despite acknowledging the benefits of shared experience, many men also discussed barriers to peer support use. These included feeling uncomfortable to share in a group, the difficulty of sustaining support groups, death of peers and the belief that support groups were focused only on emotional or psychological information.

#### Involvement of partner/family

In addition to shared experience, most men identified partners and/or family and friends as sources of support that contributed to their emotional and physical well-being. For most men, female partners were their main source of emotional and practical support. Many men discussed that partners were impacted by the diagnosis and treatment of PCa and believed it was important to involve and support partners in their care. Some men commented that partners are often the catalyst for their involvement in support groups or seeking out information/support from other sources. Broader family and friends were also discussed by some men as sources of support, often providing practical assistance.

## DISCUSSION

The present study extends previous research about the experience of men with advanced PCa, adding an additional level of description that provides insight into how health context influences men's responses, the influence of life course and ways in which masculinities is expressed in this setting. As in previous research, difficulties with accessible informational support about the disease and its treatment were highly evident.<sup>19 20 30</sup> That these problems persist and are remarkably similar in Canada,<sup>19</sup> Scotland<sup>20</sup> and in our Australian data, is striking and suggests that globally there may be a gap in health systems' responses to advanced PCa. PCa survivorship research has to date been underfunded by comparison to breast cancer<sup>31</sup>; a consensus about clinical care for advanced PCa is just now emerging<sup>32</sup> and the historical and persistent debate about the early detection of PCa<sup>23 33</sup> are likely contributors to this. The men's reports in our study of PCa having a less favourable public profile reflect this and show how the broader public health and social context can have a

profound negative impact on an already difficult cancer experience.

The influence of life course in response to illness in terms of men's age and the expression of masculinities and masculine models of coping strongly emerged in this study and this has implications for the design of care models.<sup>34</sup> We propose that there is a need to newly conceptualise and then deliver what men actually want, rather than starting from a first principle of revising services already provided that are not meeting men's needs. Men underuse psychosocial support services after cancer compared with women with breast cancer<sup>35</sup>; and previous research has suggested that interventions promoting self-management in men with chronic diseases should include action oriented approaches if they are to be used.<sup>36 37</sup> With regard to providers of support, men in the present study proposed both peer support and nurse specialists as preferred care providers, confirming previous research.<sup>38</sup>

Limitations of this study include the cross-sectional design. Recent qualitative research applying a prospective study design proposed that coping with advanced cancer evolves over time as symptoms progress and fluctuate.<sup>39</sup> Future research using a prospective case study design will add further depth to our understanding of men's experiences in the face of advancing PCa. As well, the men in our study were not newly diagnosed with advanced disease and so reports of their experience at the time of diagnosis or initial disease progression are retrospective and subject to recall bias. Strengths include a robust and transparent study method and the involvement of men across four Australian states with varied sociodemographic backgrounds such that our data can be considered broadly relevant across the Australian setting. We do note that our participant group was not ethnically diverse and so likely does not represent these experiences, that have been well described elsewhere.<sup>40</sup>

Based on our previous research<sup>18 41</sup> and the present results we propose five key content elements for inclusion in supportive care interventions with men with advanced PCa: decision support, treatment education with self-management and skills training for symptoms, including exercise prescription, routine screening for psychological distress with referral, psycho-education with tailored distress management strategies, communicating with health professionals. Strategies to integrate peer support within the care team are needed. Finally, the PCa specialist role presents as highly acceptable to men and is ideally placed for supportive care delivery and care coordination.<sup>42</sup>

In conclusion, supportive care services for men with advanced PCa need to be multimodal and take into account the influence of life course on men's illness experience. There is a need for the health system to prioritise research and development in clinical PCa care taking a more holistic approach than currently exists.

**Correction notice** This article has been corrected since it first published. In the

Abstract, "(metastatic or castration-resistant biochemical regression)" has been corrected to "(metastatic or castration-resistant biochemical progression)".

**Acknowledgements** We thank Elizabeth Eldridge and Leah Zajdlewicz for research assistance. We gratefully acknowledge the men who generously gave their time for this study.

**Contributors** SKC, JD and MKH conceived the study, developed the interview protocol, undertook the analyses and interpretation and led manuscript development. KL recruited and interviewed participants, undertook analysis and contributed to writing the manuscript. ML recruited and interviewed participants. MF, IDD and AL contributed to data interpretation. All authors contributed to revisions and approved the final manuscript.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. IDD is supported by an NHMRC Practitioner Fellowship (APP1102604).

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** Ethical approval was obtained from the Griffith University Human Research Ethics Committee (Reference number 2016/418).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** The authors have full control of all primary data and agree to allow the journal to review their data if requested.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

## REFERENCES

1. Ferlay J, Soerjomataram I, Ervik M, *et al*. *GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11*. Lyon, France: International Agency for Research on Cancer, 2013. [globocan.iarc.fr/Default.aspx](http://globocan.iarc.fr/Default.aspx) (accessed 8th Apr 2017).
2. Australian Institute of Health and Welfare. *Cancer in Australia 2017. Cancer series no. 101. Cat. No. CAN 100*. Canberra, Australia: AIHW, 2017.
3. National Cancer Institute. *SEER Cancer stat facts: prostate cancer*. Bethesda, MD: National Cancer Institute, 2016. <http://seer.cancer.gov/statfacts/html/prost.html> (accessed 8th Apr 2017).
4. Luo Q, Yu XQ, Smith DP, *et al*. A population-based study of progression to metastatic prostate cancer in Australia. *Cancer Epidemiol* 2015;39:617–22.
5. American Cancer Society. *Cancer facts & figures 2017*. Atlanta, GA: American Cancer Society, 2017.
6. Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. *Urol Oncol* 2017;35S:S1–13.
7. Heidenreich A, Bastian PJ, Bellmunt J, *et al*. *Guidelines on prostate cancer 2012*: European Association of Urology, 2012.
8. Afshar M, Evison F, James ND, *et al*. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience. *Urol Oncol* 2015;33:338.e1–7.
9. James ND, de Bono JS, Spears MR, *et al*. Abiraterone for prostate cancer not previously treated with hormone therapy. *N Engl J Med* 2017;377:338–51.
10. Fizazi K, Tran N, Fein L, *et al*. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med* 2017;377:352–60.
11. Gilbert DC, Duong T, Kynaston HG, *et al*. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. *BJU Int* 2017;119:667–75.
12. Resnick MJ, Penson DF. Quality of life with advanced metastatic prostate cancer. *Urol Clin North Am* 2012;39:505–15.
13. Bill-Axelsson A, Garmo H, Lambe M, *et al*. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a

- nationwide population-based cohort study from PCBaSe Sweden. *Eur Urol* 2010;57:390–5.
14. Bloch S, Love A, Macvean M, *et al.* Psychological adjustment of men with prostate cancer: a review of the literature. *Biopsychosoc Med* 2007;1:2.
  15. Chambers SK, Occhipinti S, Foley E, *et al.* Mindfulness-based cognitive therapy in advanced prostate cancer: a randomized controlled trial. *J Clin Oncol* 2017;35:291–7.
  16. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. *Psychooncology* 2002;11:307–26.
  17. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. *J Clin Oncol* 2001;19:72–80.
  18. Chambers SK, Hyde MK, Smith DP, *et al.* New challenges in psycho-oncology research III: A systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research implications. *Psychooncology* 2017;26:873–913.
  19. Carter N, Bryant-Lukosius D, DiCenso A, *et al.* The supportive care needs of men with advanced prostate cancer. *Oncol Nurs Forum* 2011;38:189–98.
  20. Paterson C, Kata SG, Nandwani G, *et al.* Unmet supportive care needs of men with locally advanced and metastatic prostate cancer on hormonal treatment. *Cancer Nurs* 2017;40:497–507.
  21. Chambers SK, Hyde MK, Oliffe JL, Zajdlewicz L, *et al.* Measuring masculinity in the context of chronic disease. *Psychol Men Masc* 2015;17:228–42.
  22. Chambers SK, Chung E, Wittert G, *et al.* Erectile dysfunction, masculinity, and psychosocial outcomes: a review of the experiences of men after prostate cancer treatment. *Transl Androl Urol* 2017;6:60–8.
  23. Dunn J, Casey C, Sandoe D, *et al.* Advocacy, support and survivorship in prostate cancer. *Eur J Cancer Care* 2017;1:e12644.
  24. Davidsen AS. Phenomenological approaches in psychology and health sciences. *Qual Res Psychol* 2013;10:318–39.
  25. Lopez KA, Willis DG. Descriptive versus interpretive phenomenology: their contributions to nursing knowledge. *Qual Health Res* 2004;14:726–35.
  26. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;3:77–101.
  27. Wojnar DM, Swanson KM. Phenomenology: an exploration. *J Holist Nurs* 2007;25:172–80.
  28. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007;19:349–57.
  29. Wood JV. Theory and research concerning social comparisons of personal attributes. *Psychol Bull* 1989;106:231–48.
  30. Jenkins VA, Fallowfield LJ, Jenkins VA. No man's land: information needs and resources of men with metastatic castrate resistant prostate cancer. *Support Care Cancer* 2016;24:4471–3.
  31. AIHW. *Cancer in Australia 2010: an overview*. Canberra: Australian Institute of Health and Welfare, 2010.
  32. Gillessen S, Attard G, Beer TM, *et al.* Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *Eur Urol* 2018;73:178–211.
  33. Lepor H. *Opinion makers: revisiting the USPSTF Decision on PSA Tests - Urologist Herbert Lepor, MD, sets forth 'sensible solution'*: Medpage Today, 2016.
  34. Evans J, Frank B, Oliffe JL, *et al.* Health, Illness, Men and Masculinities (HIMM): a theoretical framework for understanding men and their health. *J Mens health* 2011;8:7–15.
  35. Forsythe LP, Kent EE, Weaver KE, *et al.* Receipt of psychosocial care among cancer survivors in the United States. *J Clin Oncol* 2013;31:1961–9.
  36. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. *J Adv Nurs* 2005;49:616–23.
  37. Roesch SC, Adams L, Hines A, *et al.* Coping with prostate cancer: a meta-analytic review. *J Behav Med* 2005;28:281–93.
  38. King AJ, Evans M, Moore TH, *et al.* Prostate cancer and supportive care: a systematic review and qualitative synthesis of men's experiences and unmet needs. *Eur J Cancer Care* 2015;24:618–34.
  39. Roberts D, Calman L, Large P, *et al.* A revised model for coping with advanced cancer. Mapping concepts from a longitudinal qualitative study of patients and carers coping with advanced cancer onto Folkman and Greer's theoretical model of appraisal and coping. *Psychooncology* 2018;27:229–35.
  40. Rivas C, Matheson L, Nayoan J, *et al.* Ethnicity and the prostate cancer experience: a qualitative metasynthesis. *Psychooncology* 2016;25:1147–56.
  41. Zopf EM, Newton RU, Taaffe DR, *et al.* Associations between aerobic exercise levels and physical and mental health outcomes in men with bone metastatic prostate cancer: a cross-sectional investigation. *Eur J Cancer Care* 2017;26:e12575.
  42. Carter N, Miller PA, Murphy BR, *et al.* Healthcare providers' perspectives of the supportive care needs of men with advanced prostate cancer. *Oncol Nurs Forum* 2014;41:421–30.